Vaccine Candidates and Animal Models for Kala-Azar
DOI:
https://doi.org/10.37591/rrjoi.v5i1.1249Abstract
Kala-azar or Visceral Leishmaniasis (VL) is a serious human disease in tropical regions and rapidly emerging as an opportunistic infection in HIV patients. The available treatment against VL is associated with toxicity and drug resistance. Even though the development of vaccines against VL is received limited attention. The only successful immunization strategy in humans has been leishmanization, which is based on the development of durable immunity after recovery from infection at a chosen site, usually the arm, with viable non attenuated parasites. The use of this technique has been restricted or abandoned entirely, due to safety concerns. Researchers have applied numerous approaches to develop safe vaccines against VL using live promastigotes administered at a low dose, drug-treated attenuated Leishmania, recombinant Leishmania expressing cytokines, live parasites with CpG oligodeoxynucleotide motifs, genetically attenuated vaccines and killed Leishmania parasites with and without adjuvant. The use of live attenuated Leishmania preparations as candidate vaccines is very promising because they most closely mimic the natural course of infection and may therefore elicit similar immune responses. Leishmania mutants such as Leishmania major dhfr-ts mutant, the biopterin transporter-deficient mutant, the L. mexicana double mutant lacking both the CPA and CPB cysteine peptidase genes, L. amazonensis porphyric and L. donovani calrecitin mutants was generated for vaccine purpose. While each of these studies was mainly experimental and indicated that there is some level of protection but not complete or long-lived protection, particularly at preclinical or clinical stages. A successful approach towards a vaccine involves the requirement of Th1 subset of CD4+ cells along with Th2, CD8+, and B cells. Thus, there is an urgent need for the development of new safe vaccine against VL which would be capable of enhancing antigen presentation and eliciting potent immune responses without risk of disease development in humans.
Keywords: Leishmania donovani, vaccine candidates, approaches, feasibility, animal model
Cite this Article
Awanish Kumar. Vaccine Candidates and Animal Models for Kala-Azar. Research and Reviews: Journal of Immunology (RRJoI). 2015; 5(1): 29–35p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
